Gilead hires Roche’s pharma chief Daniel O’Day as CEORoche executive Daniel O’Day is to take the helm at Gilead after John Milligan steps down as CEO Share XGilead hires Roche’s pharma chief Daniel O’Day as CEOhttps://pharmaphorum.com/news/gilead-hires-roches-pharma-chief-daniel-oday-as-ceo/
AZ’s cancer drug fails again, Roche’s rival gets new useAstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved Share XAZ’s cancer drug fails again, Roche’s rival gets new usehttps://pharmaphorum.com/news/azs-cancer-imfinzi-fail/
UCB, Roche, and IQVIA take lead in UK life sciences investmentPharma giant UCB is to invest around £1 billion in the UK as part of a second life Share XUCB, Roche, and IQVIA take lead in UK life sciences investmenthttps://pharmaphorum.com/news/ucb-roche-and-iqvia-take-lead-in-uk-life-sciences-investment/
Genentech buys NASH biotech JecureRoche’s Genentech unit has bought California biotech Jecure Therapeutics, which is researching drugs that could be used in Share XGenentech buys NASH biotech Jecurehttps://pharmaphorum.com/news/genentech-buys-nash-biotech-jecure/
‘Generation Z’ happy to be diagnosed by chatbotsA survey involving young people from ‘Generation Z’ has revealed they want to see the NHS introduce digital Share X‘Generation Z’ happy to be diagnosed by chatbotshttps://pharmaphorum.com/news/generation-z-happy-to-be-diagnosed-by-chatbots/
Italy free to reimburse off-label Avastin, rules EU courtNovartis and Roche’s long-running battle to try to prevent off-label prescribing of Roche’s Avastin in place of their Share XItaly free to reimburse off-label Avastin, rules EU courthttps://pharmaphorum.com/news/italy-free-to-reimburse-off-label-avastin-rules-eu-court/
Gene therapy firm BioMarin stages haemophilia musicalBioMarin Pharmaceutical has put on a stage musical to raise awareness about haemophilia, and determine whether creative expression Share XGene therapy firm BioMarin stages haemophilia musicalhttps://pharmaphorum.com/news/gene-therapy-firm-biomarin-stages-haemophilia-musical/
Roche pulls extended use application for kidney cancer drugRoche has withdrawn an application to the European Medicines Agency (EMA) for an expanded use for its immunotherapy Share XRoche pulls extended use application for kidney cancer drughttps://pharmaphorum.com/news/roche-pulls-extended-use-application-for-kidney-cancer-drug/
Roche’s Tecentriq gets fast review in triple negative breast cancerThe FDA has granted a fast review for Roche/Genentech’s Tecentriq in combination with Celgene’s Abraxane for certain patients Share XRoche’s Tecentriq gets fast review in triple negative breast cancerhttps://pharmaphorum.com/news/roches-tecentriq-gets-fast-review-in-triple-negative-breast-cancer/
